EXEL
Price
$43.03
Change
+$0.66 (+1.56%)
Updated
Jun 6 closing price
Capitalization
11.73B
66 days until earnings call
ORMP
Price
$2.22
Change
+$0.07 (+3.26%)
Updated
Jun 6 closing price
Capitalization
90.69M
67 days until earnings call
Interact to see
Advertisement

EXEL vs ORMP

Header iconEXEL vs ORMP Comparison
Open Charts EXEL vs ORMPBanner chart's image
Exelixis
Price$43.03
Change+$0.66 (+1.56%)
Volume$2.34M
Capitalization11.73B
Oramed Pharmaceuticals
Price$2.22
Change+$0.07 (+3.26%)
Volume$87.55K
Capitalization90.69M
EXEL vs ORMP Comparison Chart
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. ORMP commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a StrongBuy and ORMP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (EXEL: $43.03 vs. ORMP: $2.22)
Brand notoriety: EXEL: Notable vs. ORMP: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 76% vs. ORMP: 98%
Market capitalization -- EXEL: $11.73B vs. ORMP: $90.69M
EXEL [@Biotechnology] is valued at $11.73B. ORMP’s [@Biotechnology] market capitalization is $90.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 6 bullish TA indicator(s).

  • EXEL’s TA Score: 5 bullish, 4 bearish.
  • ORMP’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ORMP is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а -0.02% price change this week, while ORMP (@Biotechnology) price change was -5.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

EXEL is expected to report earnings on Aug 12, 2025.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($11.7B) has a higher market cap than ORMP($90.7M). ORMP has higher P/E ratio than EXEL: ORMP (20.91) vs EXEL (19.65). EXEL YTD gains are higher at: 29.219 vs. ORMP (-8.264). EXEL has higher annual earnings (EBITDA): 719M vs. ORMP (9.44M). EXEL has more cash in the bank: 1.11B vs. ORMP (142M). ORMP has less debt than EXEL: ORMP (429K) vs EXEL (191M). EXEL has higher revenues than ORMP: EXEL (2.17B) vs ORMP (0).
EXELORMPEXEL / ORMP
Capitalization11.7B90.7M12,900%
EBITDA719M9.44M7,618%
Gain YTD29.219-8.264-354%
P/E Ratio19.6520.9194%
Revenue2.17B0-
Total Cash1.11B142M782%
Total Debt191M429K44,522%
FUNDAMENTALS RATINGS
EXEL vs ORMP: Fundamental Ratings
EXEL
ORMP
OUTLOOK RATING
1..100
676
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
31100
SMR RATING
1..100
4179
PRICE GROWTH RATING
1..100
3978
P/E GROWTH RATING
1..100
9250
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (58) in the Pharmaceuticals Other industry is in the same range as EXEL (73) in the Biotechnology industry. This means that ORMP’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Profit vs Risk Rating (31) in the Biotechnology industry is significantly better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew significantly faster than ORMP’s over the last 12 months.

EXEL's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for ORMP (79) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew somewhat faster than ORMP’s over the last 12 months.

EXEL's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for ORMP (78) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew somewhat faster than ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for EXEL (92) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELORMP
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
70%
Momentum
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
59%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
63%
Bearish Trend 19 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
53%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FJTSF23.612.15
+10.02%
Fujitsu Ltd.
NSANY4.970.04
+0.86%
Nissan Motor Co., Ltd.
TIIAY4.340.02
+0.46%
Telecom Italia S.p.A.
PLNH0.20N/A
-0.29%
Planet 13 Holdings Inc.
DRTTF0.63-0.02
-3.08%
Dirtt Environmental Solutions Ltd

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with ALNY. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.56%
ALNY - EXEL
34%
Loosely correlated
-2.33%
JAZZ - EXEL
34%
Loosely correlated
+2.14%
TECH - EXEL
33%
Poorly correlated
+0.79%
MRSN - EXEL
32%
Poorly correlated
+4.78%
ORMP - EXEL
32%
Poorly correlated
+3.26%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+3.26%
BTAI - ORMP
44%
Loosely correlated
+20.26%
INO - ORMP
44%
Loosely correlated
+7.08%
MBIO - ORMP
44%
Loosely correlated
-0.80%
VERV - ORMP
44%
Loosely correlated
+8.12%
ZNTL - ORMP
43%
Loosely correlated
+3.40%
More